IVAX Receives Final Approval for Bisoprolol Fumarate and Hydrochlorothiazide Tablets.

Business Editors/Health & Medical Writers

MIAMI--(BUSINESS WIRE)--Sept. 29, 2000

IVAX Corporation (AMEX:IVX) received final approval for the company's Abbreviated New Drug Application (ANDA) for bisoprolol fumarate and hydrochlorothiazide tablets in 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg strengths from the United States Food and Drug Administration (FDA). Bisoprolol fumarate and hydrochlorothiazide tablets are indicated for the treatment of hypertension and are the generic equivalent of Lederle Laboratories' Ziac(R) tablets, which have U.S. sales in excess of $200 million. IVAX will market the product through its wholly owned subsidiary, Zenith Goldline Pharmaceuticals, Inc.

IVAX Corporation, headquartered in Miami, Florida, is a holding company with subsidiaries engaged in the research, development, manufacturing, and marketing of branded and generic pharmaceuticals and veterinary and diagnostic products in the U.S. and international markets.

Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties which may affect the company's business and prospects, including the risk that Zenith Goldline Pharmaceuticals will not launch bisoprolol fumarate and hydrochlorothiazide tablets or that its launch will be delayed, and certain other risks and uncertainties based on economic, competitive, governmental, technological and other factors discussed in the Company's 1999 annual report on form 10-KA and its other filings with the Securities and Exchange Commission. Ziac(R) is a registered trademark of Lederle Laboratories.